Skip to main content
    V

    Vanda Pharmaceuticals Inc (VNDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.24
    +0.02 (+0.47%)

    Market Cap: $255.15M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    72%(28/39)
    Avg Surprise
    +166.91%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.68
    Range$-0.83 - $-0.58
    5 analysts
    EPS RevisionsNo revisions (7d)
    0
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.51-34.4%
    60d ago$-0.59-15.6%
    30d ago$-0.68-1.0%
    7d ago$-0.680.0%
    Current$-0.68
    Revenue Consensus
    $69M
    Range$61M - $76M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.07
    Range$-1.12 - $-0.96
    5 analysts
    Revenue Consensus
    $65M
    Range$56M - $78M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.07---
    Sep 26EST
    		-$-0.68---
    Jun 26
    Reported Aug 5
    		$-1.04$-0.51-103.92%Miss-126.1%
    Mar 26
    Reported May 6
    		$-0.82$-0.69-18.84%Miss-64.0%
    Dec 25
    Reported Feb 11
    		$-2.39$-1.32-81.06%Miss-2887.5%
    Sep 25
    Reported Oct 29
    		$-0.38$-0.45+15.56%Beat-322.2%
    Jun 25
    Reported Jul 31
    		$-0.46$-0.36-27.78%Miss-475.0%
    Mar 25
    Reported May 7
    		$-0.50$-0.60+16.67%Beat-614.3%
    Dec 24
    Reported Feb 13
    		$-0.08$-0.11+27.27%Beat-100.0%
    Sep 24
    Reported Nov 6
    		$-0.09$-0.16+43.75%Beat-3850.0%
    Jun 24
    Reported Jul 31
    		$-0.08N/A+61.90%Beat-366.7%
    Mar 24
    Reported May 8
    		$-0.07$0.05-240.00%Miss-216.7%
    Dec 23
    Reported Feb 7
    		$-0.04N/A+55.56%Beat-133.3%
    Sep 23
    Reported Nov 8
    		$0.00N/A+106.00%Beat-96.0%
    Jun 23
    Reported Jul 27
    		$0.03N/A+123.08%Beat-40.0%
    Mar 23
    Reported May 3
    		$0.06$0.06+0.00%Beat+154.5%
    Dec 22
    Reported Feb 8
    		$0.12$0.08+50.00%Beat+0.0%
    Sep 22
    Reported Nov 2
    		$0.06$0.09-33.33%Miss-57.1%
    Jun 22
    Reported Aug 3
    		$0.05N/A-58.33%Miss-70.6%
    Mar 22
    Reported May 5
    		$-0.11$-0.01-1000.00%Miss-173.3%
    Dec 21
    Reported Feb 23
    		$0.12$0.09+33.33%Beat-20.0%
    Sep 21
    Reported Nov 3
    		$0.14$0.18-22.22%Miss+27.3%
    Jun 21
    Reported Jul 28
    		$0.17$0.11+54.55%Beat+6.3%
    Mar 21
    Reported May 5
    		$0.15$0.14+7.14%Beat+66.7%
    Dec 20
    Reported Feb 10
    		$0.15$0.14+7.14%Beat+87.5%
    Sep 20
    Reported Oct 28
    		$0.11$0.10+10.00%Beat-94.2%
    Jun 20
    Reported Aug 5
    		$0.16$0.06+166.67%Beat-42.9%
    Mar 20
    Reported May 6
    		$0.09$0.01+800.00%Beat+50.0%
    Dec 19
    Reported Feb 25
    		$0.08$0.11-27.27%Miss-69.2%
    Sep 19
    Reported Nov 6
    		$1.91$0.07+2628.57%Beat+855.0%
    Jun 19
    Reported Jul 31
    		$0.28$0.05+460.00%Beat+100.0%
    Mar 19
    Reported May 1
    		$0.06$0.07-14.29%Miss-57.1%
    Dec 18
    Reported Feb 13
    		$0.26$0.13+100.00%Beat+766.7%
    Sep 18
    Reported Nov 7
    		$0.20$0.01+1900.00%Beat+766.7%
    Jun 18
    Reported Aug 1
    		$0.14$0.02+600.00%Beat+366.7%
    Mar 18
    Reported May 2
    		$0.14$-0.04+450.00%Beat+227.3%
    Dec 17
    Reported Feb 14
    		$0.03$-0.05+160.00%Beat+400.0%
    Sep 17
    Reported Nov 7
    		$-0.03$-0.05+40.00%Beat-
    Jun 17
    Reported Aug 2
    		$0.03N/A+115.00%Beat-
    Mar 17
    Reported May 2
    		$-0.11$-0.13+15.38%Beat-
    Dec 16
    Reported Feb 15
    		$-0.01N/A+88.89%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.92EV/EBITDAN/A
    Price/FCF-1.79xFCF Yield-56.00%
    Profitability
    Profit Margin-127.40%Operating Margin-126.30%
    ROE-77.80%ROIC-79.33%
    Financial Health
    Debt/Equity0.01xInterest CoverageN/A
    Current Ratio1.61xQuick Ratio1.60x
    Trading Statistics
    Beta0.69Avg Volume1.11M
    52-Week High$9.9452-Week Low$4.20

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.47
    SMA 20$4.76
    SMA 50$5.05
    SMA 200$6.42
    EMA 10$4.48
    EMA 20$4.68
    EMA 50$5.01
    EMA 200$5.72

    MACD

    Line: -0.24Signal: -0.19Hist: -0.05

    ADX

    ADX: 34.0+DI: 8.5-DI: 35.5

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down100.0
    PSAR$4.47

    Bollinger Bands

    Upper Band$5.41
    Lower Band$4.11
    %B Position2748%(Upper)
    Band Width0.10

    RSI (14-Day)

    Oversold
    26.5

    Momentum Oscillators

    Stoch %K7.9
    Stoch %D10.2
    Williams %R-80.5
    ROC (10d)-11.9%
    Momentum-0.57
    CCI (20d)-130.4
    MFI (14d)12.6

    Volatility Measures

    ATR (14d)$0.20(4.6%)
    StdDev (20d)0.33
    Hist Vol31.1%(Moderate)

    Volume Flow

    VWAP$4.18
    OBV45.7M
    AD Line-73.4M
    CMF (20d)-0.101

    Volume Metrics

    Avg Vol (20d)1.2M
    Vol Ratio0.9x
    VWMA (20d)$4.79

    Pivot Points

    R3$4.53
    R2$4.46
    R1$4.34
    Pivot Point$4.27
    S1$4.15
    S2$4.08
    S3$3.96

    Advanced Oscillators

    TSI-36.14
    Ultimate Osc49.9
    KST-129.34

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$50.53M$51.72M$57.22M$56.26M$52.59M$50.04M$53.19M$47.65M$50.47M$47.46M$45.27M$38.81M
    Cost of Revenue$3.56M$3.16M$3.83M$2.95M$2.74M$3.52M$2.59M$2.55M$2.73M$3.44M$3.46M$3.06M
    Gross Profit$46.97M$48.56M$53.38M$53.30M$49.85M$46.52M$50.59M$45.10M$47.74M$44.02M$41.81M$35.75M
    Operating Expenses$110.78M$98.78M$93.74M$84.59M$88.36M$87.55M$60.87M$56.10M$57.89M$53.26M$48.91M$41.75M
    R&D$36.95M$28.43M$29.01M$22.56M$21.99M$35.71M$19.84M$16.78M$16.66M$21.15M$24.34M$16.60M
    SG&A$71.84M$68.36M$62.98M$60.27M$64.62M$50.08M$39.28M$37.57M$39.47M$30.09M$23.61M$24.77M
    Operating Income$-63,809,000$-50,224,000$-40,353,000$-31,284,000$-38,503,000$-41,028,000$-10,279,000$-11,000,000$-10,146,000$-9,235,000$-7,094,000$-5,995,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-62,384,000$-48,424,000$-38,002,000$-28,390,000$-34,887,000$-37,368,000$-6,497,000$-6,244,000$-5,516,000$-4,664,000$-1,661,000$-120,000
    Income Tax Expense$129,000$143,000$103.19M$-5,804,000$-7,680,000$-7,874,000$-1,585,000$-920,000$-998,000$-518,000$739,000$-257,000
    Net Income$-62,513,000$-48,567,000$-141,187,000$-22,586,000$-27,207,000$-29,494,000$-4,912,000$-5,324,000$-4,518,000$-4,146,000$-2,400,000$137,000
    EBITDA$-58,719,000$-45,033,000$-32,395,000$-26,832,000$-32,551,000$-35,289,000$-4,372,000$-6,254,000$-5,584,000$-3,906,000$-925,000$-2,352,000
    EBIT$-62,384,000$-48,424,000$-38,002,000$-28,390,000$-34,887,000$-37,368,000$-6,497,000$-6,244,000$-5,516,000$-4,664,000$-1,661,000$-120,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VNDA

    Government Contracts

    Gov Obligations (TTM)
    -$5360
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    2
    New Awards (TTM)
    1
    Avg Remaining Term
    1.9 mo

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0025Department of Veterans AffairsDepartment of Veterans Affairs$26344Oct 1, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

    Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced that its experimental anxiety treatment, VQW-765, failed to meet its primary and secondary endpoints in a Phase 3 trial. The drug, intended for acute social anxiety...

    Benzinga•10/15/26•Bearish

    Vanda Pharmaceuticals puts VQW-765 on hold. Vanda Pharmaceuticals stock costs EUR 3.62

    Vanda Pharmaceuticals has put its VQW-765 Phase III study on hold after it failed to meet both primary and secondary endpoints in adults with social anxiety disorder. This clinical setback follows a decline...

    ad-hoc-news.de•10/15/26•Bearish

    MILLENNIUM MANAGEMENT LLC Adds to Vanda Pharmaceuticals Inc (VNDA) Position -- Shares Look 25% Undervalued on GF Value

    MILLENNIUM MANAGEMENT LLC increased its stake in Vanda Pharmaceuticals Inc (VNDA) by 26.17% on September 30, 2026, purchasing 883,637 shares at $4.91 each. The firm now holds 4,260,038 shares...

    GuruFocus•10/15/26•Somewhat-Bullish

    Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

    Vanda Pharmaceuticals announced that its experimental drug, VQW-765, failed to meet the primary goal of a late-stage study for social anxiety disorder. The drug did not reduce anxiety compared to a placebo...

    Yahoo Finance•10/14/26•Bearish

    Vanda Pharmaceuticals' Late-Stage Study of VQW-765 to Treat Acute Anxiety Fails to Meet Primary Endpoint

    Vanda Pharmaceuticals announced that its late-stage study of VQW-765, a candidate for treating acute anxiety, did not meet its primary endpoint. The article, provided by MT Newswires...

    Yahoo Finance•10/14/26•Bearish

    VNDA Valuation and Fair Value

    P/E
    -0.9x
    Forward P/E
    103.1x
    P/FCF
    -1.8x
    PEG
    2.2x
    P/B
    1.2x
    See GNG's fair value

    VNDA Profitability: Margins, ROIC and FCF

    Gross margin
    93.7%
    Operating margin
    -126.3%
    Net margin
    -127.4%
    ROIC
    -79.3%
    ROE
    -77.8%
    FCF margin
    -66.3%
    FCF yield
    -56.0%

    VNDA Competitors

    CompanyTicker
    OraSure Technologies IncOSUR
    Inhibikase Therapeutics IncIKT
    EyePoint, IncEYPT
    Century Therapeutics IncIPSC
    Prelude Therapeutics IncPRLD
    BioAge Labs, IncBIOA
    Palisade Bio IncPALI
    So-Young International IncSY

    Sector: Healthcare

    VNDA Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    0
    Buy
    4
    Hold
    1
    Sell
    0
    Strong Sell
    0

    VNDA Bull Case vs Bear Case

    Bull case

    • 80.0% of VNDA's analyst ratings are Buy or Strong Buy.

    Bear case

    • VNDA has a -127.4% net profit margin.
    • VNDA's quarterly revenue changed -3.9% year over year.

    VNDA Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -16.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.68
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 4 down

    Frequently Asked Questions About VNDA

    Does VNDA pay dividends?

    Vanda Pharmaceuticals Inc (VNDA) does not currently pay a regular dividend.

    What is VNDA's market cap?

    Vanda Pharmaceuticals Inc (VNDA) has a market capitalization of $255.15M with a current stock price of $4.24.

    Related stocks

    Sector: Healthcare

    All stocks starting with V

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In